Rosemont Pharmaceuticals, a developer of liquid medicines, has announced the acquisition of Pharma-Data, a research and development organisation based in Lavrion, Greece, enhancing its ability to develop products for worldwide market.
Amneal Pharmaceuticals has initiated the distribution of its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, to retail pharmacies across the US, including the State of California.
Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical, granting the latter exclusive rights to commercialise Sol-Gel’s dermatology product TWYNEO in mainland China, Taiwan, Hong Kong, Macau, and Israel.
Scorpius Holdings, an integrated contract development and manufacturing organisation (CDMO), has confirmed the successful current Good Manufacturing Practice (cGMP) facility validation for microbial manufacturing.
PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.
IMA Life North America is set to establish a new $30m facility in Tonawanda, New York, US, aimed at increasing its production capabilities for pharmaceutical freeze-drying equipment.
Biocon, an India-based biopharmaceutical company, has entered into an exclusive licensing and supply agreement with Brazilian specialty pharmaceutical company Biomm for the commercialisation of Semaglutide (gOzempic), a drug used to improve glycemic control in adults with type-2 diabetes.
Sanofi India Limited and Sanofi Healthcare India (together called “Sanofi India”) have entered into an exclusive partnership with Cipla, focusing on the expansion of its central nervous system (CNS) product portfolio in the Indian market.
Merck has announced the opening of a new €20m ($21.7m) distribution centre in Cajamar, São Paulo, Brazil, for serving its Life Science customers in the region.
Aizon, an artificial intelligence (AI) Software as a Service (SaaS) provider for pharmaceutical manufacturing operations, has secured $20m in Series C funding to expedite its development pipeline.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.